Optimizing Treatment in Low Myopes
-
By
-
Brooke M. Messer, OD, FSLS, FAAO
-
March 1, 2026
-
3 min
By
Brooke M. Messer, OD, FSLS, FAAO
March 1, 2026
Ahead of phase 3 myopia push, late clinical-stage biopharmaceutical company takes on Thomas Ruggia as Chief Executive Officer
May 18, 2026